Anbio Biotechnology (NNNN) is up 11.2%, or $3.13 to $31.14. Published first on TheFly – the ultimate source for real-time, market-moving breaking ...

After years on the sidelines while investors piled into the next big thing in AI or crypto, biotech is back in focus. The question is whether this rally marks a real recovery or just another ...

Anbio Biotechnology is a medical device firm specializing in in-vitro diagnostics, with recent stock volatility and a thin public float. I believe they continue to face significant regulatory hurdles ...

In September 2024, Akeso, a little-known Chinese biopharmaceutical company, announced that clinical trials had shown that its new drug could halt the progression of a type of lung cancer for nearly a ...

The portfolio generated interest among veterinarians, distributors, and industry participants. The dry chemiluminescence and fluorescence immunoassay systems were noted for their precision and ...

China’s biotech sector is surging. For the first time, it now leads the world in clinical trials and new drug licensing. The U.S., once the undisputed leader in pharmaceutical innovation, risks losing ...